Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Pfizer acquired the candidate following a bidding war with obesity giant Novo Nordisk for Metsera.

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks ...

Ultimately the committee must decide who is considered at high enough risk for an extra dose. Data provided by Pfizer and the ...

Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and ...

New clinical data supports ERLEADA for metastatic castration sensitive prostate cancer, reinforcing its role in current ...

According to public statements and social media posts from X, ACIP vice chair Robert Malone (a public ally of HHS secretary Robert F. Kennedy Jr.) publicly accused FDA Commissioner Marty Makary of ...

During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal ...